1. Home
  2. NMG vs GYRE Comparison

NMG vs GYRE Comparison

Compare NMG & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nouveau Monde Graphite Inc.

NMG

Nouveau Monde Graphite Inc.

HOLD

Current Price

$1.91

Market Cap

671.4M

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$6.64

Market Cap

679.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMG
GYRE
Founded
2011
2002
Country
Canada
United States
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
671.4M
679.4M
IPO Year
2015
2004

Fundamental Metrics

Financial Performance
Metric
NMG
GYRE
Price
$1.91
$6.64
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$5.75
$17.00
AVG Volume (30 Days)
946.2K
59.0K
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$275,000.00
Revenue This Year
N/A
$19.88
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.60
$6.58
52 Week High
$6.06
$11.61

Technical Indicators

Market Signals
Indicator
NMG
GYRE
Relative Strength Index (RSI) 40.72 37.19
Support Level $1.81 N/A
Resistance Level $2.00 $8.26
Average True Range (ATR) 0.11 0.38
MACD -0.02 -0.10
Stochastic Oscillator 25.56 3.27

Price Performance

Historical Comparison
NMG
GYRE

About NMG Nouveau Monde Graphite Inc.

Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The Company currently operates in two segments: the Mining projects (which includes the Matawinie Mine project and the Uatnan Mining Project) and the Battery Material Plant project.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: